Helix Acquisition Corp

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch HLXB and buy or sell other stocks, ETFs, and their options commission-free!

About HLXB

Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. 

CEO
Eli M. Wallace, PhD
CEOEli M. Wallace, PhD
Employees
Employees
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
Founded
Employees
Employees

HLXB Key Statistics

Market cap
784.05M
Market cap784.05M
Price-Earnings ratio
-13.57
Price-Earnings ratio-13.57
Dividend yield
Dividend yield
Average volume
222.26K
Average volume222.26K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$14.87
52 Week high$14.87
52 Week low
$8.70
52 Week low$8.70

Stock Snapshot

As of today, Helix Acquisition Corp(HLXB) shares are valued at $9.90. The company's market cap stands at 784.05M, with a P/E ratio of -13.57.

Helix Acquisition Corp(HLXB) stock opened on 2025-12-13 at —. The price climbed to — and dipped to —.

Helix Acquisition Corp(HLXB) shares are trading with a volume of 0, against a daily average of 222.26K.

In the last year, Helix Acquisition Corp(HLXB) shares hit a 52-week high of $14.87 and a 52-week low of $8.70.

In the last year, Helix Acquisition Corp(HLXB) shares hit a 52-week high of $14.87 and a 52-week low of $8.70.

People also own

Based on the portfolios of people who own HLXB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.